1. Role: Associate Dean. Scope: College. Description: Lead research enterprise of the College of Pharmacy. Represent the College at the HSC level. Mentor researchers. Date: 2020.
Vibhudutta Awasthi, Ph.D.
Professor and Associate Dean for Research
Pharmaceutical Sciences
Phone (405) 271-6593 x47331
Fax (405) -271-7505
Office CPB 309
Summary
My research interests are in the development of radiopharmaceuticals, small animal imaging and use of radiological imaging techniques to answer physiological questions. My current research focuses on the development of liposome encapsulated hemoglobin as an artificial oxygen carrier and he is studying cerebral oxygen metabolism using positron emission tomography. I am a board certified nuclear pharmacist with expertise in areas related to drug delivery, formulation development, nuclear pharmacy and small animal nuclear imaging.
Publications & Presentations
- 56. Pathuri G, Madka V, Hedrick A F, Lightfoot S A, Awasthi V, Cowley, Jr B D, Rao C V, Gali H. Evaluation of 99mTc-probestin SPECT as a novel technique for noninvasive imaging of kidney aminopeptidase N expression. Mol Pharm. 2014; 11 : 2948-2953
57. Awwad H O, Simpson-Durand C D, Gonzalez L P, Tompkins P, Zhang Y, Lerner M, Brackett D J, Sherry D M, Awasthi V, Standifer K. Post-blast treatment with Nociceptin/Orphanin FQ peptide receptor antagonist reduces traumatic brain injury-induced cerebral hypoxia. Neuroscience 2014 program and website. 2014
58. Yadav V R, Hussain A, Kaustuv S, Awasthi V. Remediation of hemorrhagic shock-induced intestinal barrier dysfunction by treatment with diphenyldihaloketones EF24 and CLEFMA. J Pharmacol Exp Ther. 2014; 351 : 413-422
59. Vilekar P, King C, Lagisetty P, Awasthi V, Awasthi S. Antibacterial activity of synthetic curcumin derivatives: 3,5-bis(benzylidene)-4-piperidone (EF24) and EF24-dimer linked via diethylenetriaminepentacetic acid (EF2DTPA). Appl Biochem Biotech. 2014; 172 : 3363-73
60. Yadav V, Sahoo K, Awasthi V. Pre-clinical evaluation of CLEFMA, 4-(3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid in a mouse model of lung cancer xenograft. Br J Pharmacol. 2013; 170 : 1436–1448
Grants
- 1. Developing PPARγ acetylation inhibitor for the treatment of aging-related conditions. NIH. Start Date: 2021. End Date: 2026.
2. Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment. NIH. Start Date: 2021. End Date: 2026.
3. SBIR Phase I: Early-Stage Development of GPPD for Fatty Liver. NIH.
4. Surfactant protein-A regions as TLR4-immunomodulators. NIH. Start Date: 2017. End Date: 2023.
5. STTR Phase I: Cardiotropic Atorvastatin Liposomes for Myocardial Reperfusion Injury. NSF. Start Date: 2023. End Date: 2021.
Awards and Honors
- 1. USPTO. Patent application issued. Date: 2015.
2. Journal of Pharmaceutical Sciences. Article selected as a featured research paper. Date: 2015.
3. Robert Glenn Rapp Foundation. Presidential Professor . Date: 2013.
4. Sandra K and David L Gilliland Chair in Nuclear Pharmacy . Date: 2012.
Education
- 1. Degree: Ph D. Sanjay Gandhi Postgraduate Institute of Medical Sciences . Date: 1994.
2. Degree: M. Pharm.. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1990.
3. Degree: B. Pharm. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1988.
Administrative Assignments
2. Role: Director. Scope: University. Description: Direction and conduct of nuclear imaging services for biomedical investigators; Production of PET radiotracers for preclinical imaging and preparation for regulatory compliance for clinical applications; Consultations with researchers about imaging and tracer applications. Date: 2007.
External Connections and Partnerships
no results